Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CTCL Is Rare, Incurable, and Potentially Lethal in Advanced Stages

August 31st 2022

Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased steadily since the 1970s.

Approval Sought for Tafasitamab/Lenalidomide Combo in R/R DLBCL in Hong Kong

August 31st 2022

The Hong Kong Special Administrative Region’s Department of Health has accepted for review a biologics license application seeking the approval of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Frontline Pivekimab Sunirine Demonstrates Significant Activity in Blastic Plasmacytoid Dendritic Cell Neoplasm

August 31st 2022

First-line treatment with pivekimab sunirine generated responses with favorable tolerability in patients with blastic plasmacytoid dendritic cell neoplasm, according to data from the phase 2 CADENZA trial.

Women in Oncology: Prioritization and Passionate Legacies

August 30th 2022

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

FDA Allows Trial Enrollment to Resume for Single-Agent Emavusertib in AML/MDS

August 30th 2022

The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS

August 30th 2022

Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.

Daiichi Sankyo Submits sNDA for Quizartinib in Newly Diagnosed FLT3-ITD+ AML in Japan

August 30th 2022

Daiichi Sankyo submitted a supplemental new drug application to Japan’s Ministry of Health, Labor, and Welfare for the use of quizartinib in patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia.

Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

August 29th 2022

The combination of plinabulin and pegfilgrastim was well tolerated patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation and who have received a high dose of melphalan.

EU Approves Asciminib for Ph+ CML in Chronic Phase After 2 or More TKIs

August 29th 2022

The European Commission has approved asciminib for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who received prior treatment with at least 2 TKIs

Using Multidisciplinary Care to Optimize Outcomes in GVHD

August 29th 2022

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Daratumumab Plus RVd Improves Clinical Outcomes in Transplant-Eligible, Newly Diagnosed Multiple Myeloma

August 28th 2022

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma

August 28th 2022

Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.

Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data

August 27th 2022

Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.

Post-Transplant Carfilzomib Plus Lenalidomide/Dexamethasone Provides Superior PFS Benefit Over Lenalidomide in Myeloma

August 26th 2022

Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26th 2022

The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.

FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

August 26th 2022

The FDA has approved pemigatinib (Pemazyre) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement.

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25th 2022

Patients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.

Other Novel Therapeutic Agents in Immune Thrombocytopenia

August 25th 2022

Before closing out their discussion on novel treatment approaches in ITP, experts review data behind FcR-, BTK-, and CD38-targeted therapies.

Novel Treatment Strategies in Immune Thrombocytopenia: Complement Inhibitors

August 25th 2022

Panelists review data behind sutimlimab, a complement inhibitor being investigated in the setting of immune thrombocytopenia.